Organogenesis (NASDAQ:ORGO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Organogenesis (NASDAQ:ORGO) from a strong sell rating to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.

A number of other brokerages also recently commented on ORGO. UBS Group set a $3.00 price objective on Organogenesis in a research report on Thursday, May 28th. Truist Financial lowered their price objective on Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Finally, Weiss Ratings lowered Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 4th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $4.33.

Organogenesis Stock Performance

NASDAQ:ORGO opened at $1.40 on Friday. The firm’s 50-day moving average is $1.96 and its 200-day moving average is $2.29. Organogenesis has a 52-week low of $1.34 and a 52-week high of $7.08. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.00 and a current ratio of 3.52. The company has a market cap of $180.15 million, a price-to-earnings ratio of -1.63 and a beta of 1.29.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, August 6th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.36). Organogenesis had a negative net margin of 19.94% and a negative return on equity of 23.89%. The company had revenue of $43.76 million during the quarter, compared to the consensus estimate of $54.27 million.

Institutional Trading of Organogenesis

A number of large investors have recently bought and sold shares of ORGO. Waverly Advisors LLC acquired a new position in Organogenesis in the second quarter valued at about $25,000. Sequoia Financial Advisors LLC bought a new position in shares of Organogenesis during the 2nd quarter valued at about $33,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Organogenesis in the 4th quarter valued at approximately $75,000. Pallas Capital Advisors LLC bought a new stake in Organogenesis during the 2nd quarter worth approximately $37,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Organogenesis during the 2nd quarter worth approximately $44,000. 49.57% of the stock is currently owned by institutional investors.

About Organogenesis

Organogenesis Holdings Inc is a biotechnology company focused on regenerative medicine products for wound care, surgical procedures and sports medicine. The company develops and commercializes biologically derived products designed to support tissue repair and healing.

Its advanced wound care portfolio includes Apligraf, a living cellular skin substitute used in the treatment of certain chronic wounds, as well as products such as Dermagraft, Affinity, NuShield and other wound coverings and tissue matrices.